Citadel Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-955,818
| Closed | -$39.1M | – | 7021 |
|
|
2024
Q2 | $39.1M | Buy |
955,818
+871,933
| +1,039% | +$35.7M | 0.01% | 578 |
|
|
2024
Q1 | $3.55M | Sell |
83,885
-169,747
| -67% | -$7.18M | ﹤0.01% | 2033 |
|
|
2023
Q4 | $10.8M | Buy |
253,632
+102,704
| +68% | +$4.35M | ﹤0.01% | 1177 |
|
|
2023
Q3 | $3.29M | Buy |
150,928
+65,049
| +76% | +$1.42M | ﹤0.01% | 1960 |
|
|
2023
Q2 | $2.73M | Buy |
85,879
+51,446
| +149% | +$1.64M | ﹤0.01% | 2182 |
|
|
2023
Q1 | $840K | Buy |
34,433
+30,233
| +720% | +$737K | ﹤0.01% | 3354 |
|
|
2022
Q4 | $132K | Sell |
4,200
-61,221
| -94% | -$1.93M | ﹤0.01% | 4890 |
|
|
2022
Q3 | $1.85M | Sell |
65,421
-400,613
| -86% | -$11.3M | ﹤0.01% | 2819 |
|
|
2022
Q2 | $12.3M | Buy |
466,034
+448,943
| +2,627% | +$11.9M | ﹤0.01% | 1130 |
|
|
2022
Q1 | $598K | Sell |
17,091
-326,353
| -95% | -$11.4M | ﹤0.01% | 4271 |
|
|
2021
Q4 | $11.1M | Sell |
343,444
-238,871
| -41% | -$7.74M | ﹤0.01% | 1371 |
|
|
2021
Q3 | $17.2M | Sell |
582,315
-169,850
| -23% | -$5.01M | ﹤0.01% | 1017 |
|
|
2021
Q2 | $19.3M | Sell |
752,165
-474,564
| -39% | -$12.2M | ﹤0.01% | 981 |
|
|
2021
Q1 | $16.8M | Sell |
1,226,729
-154,827
| -11% | -$2.13M | ﹤0.01% | 1041 |
|
|
2020
Q4 | $22.9M | Buy |
+1,381,556
| New | +$22.9M | 0.01% | 783 |
|